10x Genomics $TXG Shares Newly Bought by Guardian Partners Inc.

Guardian Partners Inc. purchased a new stake in 10x Genomics (NASDAQ:TXG) in the third quarter, Holdings Channel reports. The institutional investor purchased 18,000 shares of the company’s stock, valued at approximately $1,626,000.

Several other large investors also recently made changes to their positions in the business. Quantinno Capital Management LP boosted its position in shares of 10x Genomics by 16.0% during the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after purchasing an additional 744,558 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of 10x Genomics by 34.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after purchasing an additional 525,369 shares in the last quarter. Counterpoint Mutual Funds LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $11,364,000. Quantedge Capital Pte Ltd raised its holdings in shares of 10x Genomics by 104.2% in the 1st quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after purchasing an additional 212,600 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in 10x Genomics during the first quarter valued at approximately $5,945,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Up 5.8%

Shares of NASDAQ TXG opened at $75.59 on Thursday. 10x Genomics has a 12 month low of $12.08 and a 12 month high of $102.81. The company has a market cap of $9.85 billion, a price-to-earnings ratio of -128.12 and a beta of 1.99. The business has a fifty day simple moving average of $71.95 and a 200-day simple moving average of $46.74.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to analyst estimates of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. 10x Genomics’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same quarter last year, the company posted $0.28 EPS. As a group, sell-side analysts expect that 10x Genomics will post -0.75 EPS for the current fiscal year.

Analysts Set New Price Targets

TXG has been the subject of a number of research reports. Citigroup raised their target price on shares of 10x Genomics from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Leerink Partners lifted their price target on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 29th. Piper Sandler lifted their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the stock a “neutral” rating in a research report on Monday, September 28th. Stifel Nicolaus set a $70.00 price target on 10x Genomics in a report on Tuesday, October 13th. Finally, Argus assumed coverage on 10x Genomics in a report on Monday, September 28th. They issued a “buy” rating and a $110.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, 10x Genomics currently has a consensus rating of “Hold” and an average price target of $68.00.

Insider Activity

In other news, insider Benjamin J. Hindson sold 13,818 shares of 10x Genomics stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the transaction, the insider directly owned 488,182 shares of the company’s stock, valued at $30,765,229.64. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John R. Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the transaction, the director directly owned 328,436 shares in the company, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is owned by company insiders.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.